TITLE

Pharmacovigilance Analysis of Adverse Psychiatric Events and Suicidality Reported for Roflumilast, an Add-On COPD Therapy

AUTHOR(S)
Ali, Ayad K.
PUB. DATE
October 2013
SOURCE
British Journal of Pharmaceutical Research;Oct-Dec2013, Vol. 3 Issue 4, p972
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Aims: Roflumilast is a phosphodiesterase-4-inhibitor used as add-on therapy to long- acting bronchodilators in chronic obstructive pulmonary disease. Although roflumilast is well tolerated, there have been concerns regarding psychiatric problems, including suicide tendencies. This study aims to identify and characterize signals of adverse psychiatric events reported for roflumilast in the US FDA Adverse Event Reporting System (FAERS). Study Design: Retrospective pharmacovigilance analysis. Place and Duration of Study: Adverse event reports submitted to FAERS from October 1997 through September 2012. Methodology: Multi-item Gamma Poisson Shrinker data-mining algorithm was applied to adverse psychiatric events (APE) that were submitted to the FAERS (3Q1997-3Q2012). Empirical Bayes Geometric Mean (EBGM) and 95% confidence interval (EB05-EB95) were calculated for roflumilast-associated APE compared to all drugs in FAERS. The following Preferred Terms of the MedDRA terminology were used to define the outcome of interest: "anxiety", "depressed mood", "depression", "insomnia", "suicide attempt", and "suicidal ideation". Signals with EB05 ≥2 are considered significant disproportional reporting (≥ twice that expected) of APE. Results:126 reports of APE were identified for roflumilast, corresponding to mutually non- exclusive events of insomnia (n=53), anxiety (n=38), depression (n=36), suicidal ideation (n=30), depressed mood (n=8), and suicide attempt (n=6). EBGM (EB05-EB95) were: APE, 3.55 (3.06-4.11); insomnia, 4.55 (3.62-5.66); anxiety, 2.96 (2.26-3.82); depression, 2.88 (2.19-3.75); suicidal ideation, 5.65 (4.16-7.52); depressed mood, 3.90 (2.20-6.53); and suicide attempt, 1.66 (0.86-2.95). Conclusion: Roflumilast is associated with higher than expected reporting of APE, including suicidal thoughts, but not suicide attempts. Given the inherent confounding and bias limitations of spontaneous reporting systems, pharmacoepidemiologic studies are required to test these hypotheses; meanwhile, prescribers should consider alternative add-on therapies to patients with past or present depression or suicidality.
ACCESSION #
90542420

 

Related Articles

  • A multidisciplinary intervention to reduce antibiotic duration in lower respiratory tract infections. Murray, Colin; Shaw, Arlene; Lloyd, Matthew; Smith, Robin P.; Fardon, Thomas C.; Schembri, Stuart; Chalmers, James D. // Journal of Antimicrobial Chemotherapy (JAC);Feb2014, Vol. 69 Issue 2, p515 

    Objectives Prolonged antibiotic courses are common in patients with lower respiratory tract infections (LRTIs) and contribute to antibiotic resistance and side effects. This study describes a multidisciplinary intervention to reduce antibiotic duration in LRTI patients. Methods This was a...

  • Prophylactic Antibiotic Therapy in Chronic Obstructive Pulmonary Disease. Herath, Samantha C.; Poole, Phillippa // JAMA: Journal of the American Medical Association;6/4/2014, Vol. 311 Issue 21, p2225 

    The article discusses a study that reviewed 7 randomized clinical trials (RCT) on prophylactic antibiotic use in chronic obstructive pulmonary disease (COPD). Topics discussed include the association between macrolide prophylaxis and lower incidence of exacerbations, continuous and pulsed...

  • Phenotype-guided treatment of COPD. Is it the future or the present? Miravitlles, Marc // Hot Topics in Respiratory Medicine;2012, Issue 22, p13 

    The term phenotype as applied to chronic obstructive pulmonary disease (COPD) is defined as "those attributes of the disease that, alone or combined, describe the differences in clinically meaningful parameters between individuals with COPD". Among those described, there are four that are...

  • Pulmonary rehabilitation in patients with MRC Dyspnoea Scale 2. Man, W. D.-C.; Grant, A.; Hogg, L.; Moore, J.; Barker, R. D.; Moxham, J. // Thorax;Mar2011, Vol. 66 Issue 3, p263 

    A letter to the editor is presented which is concerned with research which investigated pulmonary rehabilitation in patients with chronic obstructive pulmonary disease.

  • Antipsychotic-induced elevation of creatine kinase: a systematic review of the literature and recommendations for the clinical practice. Laoutidis, Zacharias; Kioulos, Kanellos // Psychopharmacology;Nov2014, Vol. 231 Issue 22, p4255 

    Rationale: The primary antipsychotic-induced creatine kinase elevation (i.e., not due to neuroleptic malignant syndrome, extrapyramidal symptoms, etc.) is a poorly studied condition. Objectives: The aims of the present study were to provide an overview of published cases with...

  • Healthy diet may help COPD.  // Focus on Healthy Aging;Aug2014, Vol. 17 Issue 8, p2 

    The article reports on the study indicating the health benefits of having healthy diet in addressing chronic obstructive pulmonary disease.

  • Glycopyrronium dominates tiotropium in Sweden and Spain.  // PharmacoEconomics & Outcomes News;Nov2013, Issue 691, p9 

    The article discusses the results of two studies sponsored by pharmacology company Novartis into the cost effectiveness of glycopyrronium as a treatment for chronic obstructive pulmonary disease.

  • ALZHEIMER'S DRUGS DOUBLE DEATH RISK IN ELDERLY, RESEARCHERS SAY.  // Psychiatry (1550-5952);Feb2009, Vol. 6 Issue 2, p13 

    The article reports on a new study which suggests that antipsychotic drugs commonly used to treat Alzheimer's disease may double death risk in elderly patients. It infers that antipsychotic drugs which can help control the hallucinations and aggression for a few months increased the risk of...

  • MitoPark mice, an animal model of Parkinson's disease, show enhanced prepulse inhibition of acoustic startle and no loss of gating in response to the adenosine A antagonist SCH 412348. Grauer, Steven; Hodgson, Robert; Hyde, Lynn // Psychopharmacology;Apr2014, Vol. 231 Issue 7, p1325 

    Rationale: Psychoses are debilitating side effects associated with current dopaminergic treatments for Parkinson's disease (PD). Prepulse inhibition (PPI), in which a non-startling stimulus reduces startle response to a subsequent startle-eliciting stimulus, is important in filtering out...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics